Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
SpendRule raises $2M, emerges from stealth to help hospitals track spending

From TechCrunch

By Dominic-Madori Davis

February 17, 2026

SpendRule raises $2M, emerges from stealth to help hospitals track spending

SpendRule raises $2M, emerges from stealth to help hospitals track spending

Last year, Chris Heckler was coming to the end of a five-year non-compete after selling his last company, a healthcare startup. “I was sitting on the sidelines doing angel investing, and I realized I was too young to retire,” he told TechCrunch. “I wanted to get back into it.” 

At the same time, Joseph Akintolayo had just sold his fintech company. He, too, had a non-compete, but was noodling on ideas for a company. He knew Heckler, as Akintolayo had once served as an advisor on one of his projects. 

In this downtime, however, they wanted to come together — Heckler, with his connections, and Akintolayo, with his knowledge of AI and supply chains — to try and build something new. 

The result was SpendRule, launched last summer as an AI-powered platform that helps healthcare systems track their spending. The company emerged from stealth on Tuesday, with $2 million in funding in a round led by Abundant Venture Partners. Others in the round include MemorialCare Innovation Fund and Zeal Capital Partners.

Right now, if an item has a barcode, health systems use a three-way match, Akintolayo, the company’s CTO, said, which connects a purchase to an invoice. But a lot of the time, health systems have purchases and contracts (such as maintenance, janitorial, translation services, or laundry) that lack bar codes or easily identifiable purchase receipts. 

Because these types of purchases can often be tricky and complex to manage, overspending is quite common. SpendRule is a technology that ensures hospitals pay only what was negotiated in their contracts. It is integrated with and operates on top of a hospital system’s current enterprise resource planning software, contract management software, and accounts payable workflows, pulling information from contracts, invoices, internal databases, and vendor data to validate invoices before payment is released.

It flags discrepancies and tells teams when to pay and when not to. Typically, hospitals hire an auditor every two years to perform this function or manually review each invoice. It was a tedious task bound to be automated in this current wave of AI. Already, big names like Kettering Health, MemorialCare, and MUSC Health are using the platform, Akintolayo said. 

Heckler and Akintolayo started the company only last summer but managed to close a round by Halloween, mainly due to Heckler’s industry connections. “We were able to painlessly close that initial round and use that to grow the team to support the customers,” he said. The new capital will be used to hire and continue developing the company’s AI infrastructure. 

Heckler said SpendRule considers existing invoice auditors its competition, such as SpendMend and GHX. But Akintolayo said again, one main difference is SpendRule’s focus on purchase services, the type of items hospitals buy that do not have barcodes. 

“Our goal is to build a more resilient hospital system,” Akintolayo said. “That’s our vision. To protect the bottom line of everyone by connecting their data and helping them make better decisions.” 

View original article on techcrunch.com

Most Recent

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Ryan Beiermeister, who demonstrated cool analysis in the Founders Fund YouTube series "Mafia," has joined the firm as a partner.

Jul 16, 2026

Similar Posts

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

When it comes to data, perhaps no sector has as much of it and in as many distinct silos as the healthcare industry. Hundreds of millions of patient records reside within various electronic health records (EHRs) maintained by vendors like Epic, Cerner and Athena. Insurance companies hold extensive data sets on coverage, reimbursement rates, and patient demographics. Pharmacies and laboratories contribute further data points on medication usage and diagnostic results. Over the last decade or so

Jan 9, 2025

Eppo lands new cash to grow its app, website and AI experimentation business

Eppo lands new cash to grow its app, website and AI experimentation business

The AI industry continues to release tons of new models, and companies looking to stay competitive are racing to adopt them for their purposes. In fact, nearly 10% of businesses plan to spend a whopping $25 million this year on AI initiatives, according to tech consulting firm Searce. But while lots of money is being spent on AI, it’s unclear the ROI is there. Half of all AI leaders aren’t sure how to calculate or demonstrate the value of AI projects, according to Gartner. Ex-Airbnb data scient

Aug 20, 2024

Lotus Health nabs $35M for AI doctor that sees patients for free

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI, a startup building AI solutions that can handle non-diagnostic patient-facing tasks, secured a massive $141 million Series B at a valuation of $1.64 billion led by Kleiner Perkins, the company announced Thursday. The funding comes nine months after Hippocratic AI raised a $53 million round from General Catalyst and Andreessen Horowitz and five months after raising $17 million from Nvidia. The startup is less than two years old. While most healthcare-generative AI companies focus

Jan 9, 2025

Most Recent

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Ryan Beiermeister, who demonstrated cool analysis in the Founders Fund YouTube series "Mafia," has joined the firm as a partner.

Jul 16, 2026

Similar Posts

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

When it comes to data, perhaps no sector has as much of it and in as many distinct silos as the healthcare industry. Hundreds of millions of patient records reside within various electronic health records (EHRs) maintained by vendors like Epic, Cerner and Athena. Insurance companies hold extensive data sets on coverage, reimbursement rates, and patient demographics. Pharmacies and laboratories contribute further data points on medication usage and diagnostic results. Over the last decade or so

Jan 9, 2025

Eppo lands new cash to grow its app, website and AI experimentation business

Eppo lands new cash to grow its app, website and AI experimentation business

The AI industry continues to release tons of new models, and companies looking to stay competitive are racing to adopt them for their purposes. In fact, nearly 10% of businesses plan to spend a whopping $25 million this year on AI initiatives, according to tech consulting firm Searce. But while lots of money is being spent on AI, it’s unclear the ROI is there. Half of all AI leaders aren’t sure how to calculate or demonstrate the value of AI projects, according to Gartner. Ex-Airbnb data scient

Aug 20, 2024

Lotus Health nabs $35M for AI doctor that sees patients for free

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI, a startup building AI solutions that can handle non-diagnostic patient-facing tasks, secured a massive $141 million Series B at a valuation of $1.64 billion led by Kleiner Perkins, the company announced Thursday. The funding comes nine months after Hippocratic AI raised a $53 million round from General Catalyst and Andreessen Horowitz and five months after raising $17 million from Nvidia. The startup is less than two years old. While most healthcare-generative AI companies focus

Jan 9, 2025